Xellia, FDA Modify Consent Decree; Site Can Resume Production by 2017

By Sam | June 13, 2016

Xellia Pharmaceuticals and the FDA have agreed on a modified consent decree so Xellia can resume manufacturing at the Bedford, Ohio, site it purchased from Ben Venue Laboratories.
Source: Drug GMP Report

Posted in Drug GMP Report